Skip to content

Nadolol/Bendroflumethiazide

    Brands

    DEA Class;  Rx

    Common Brand Names; Corzide

    • Thiazide Combos; 
    • Beta-Blocker/Thiazide Diuretic Combos

    Beta-blocker and thiazide diuretic combination indicated for HTN; nadolol is a nonselective and hydrophilic beta-blocker lacking significant ISA or MSA, and is renally eliminated.

    Indicated for the treatment of hypertension in patients who do not respond to monotherapy.

    Anuria

    Cardiogenic shock

    Heart block 2°/3°

    Hypersensitivity to either component or sulfonamides

    Overt cardiac failure

    Sinus bradycardia

    Uncompensated cardiac failure

    Asthma

    No adverse effects specific to the combination have been observed; adverse effects limited to those previously reported with nadolol and bendroflumethiazide

    Nadolol

    • Abdominal discomfort
    • Constipation
    • Diarrhea
    • CHF
    • Nausea
    • Cough
    • Nasal congestion
    • Drowsiness
    • Insomnia
    • Palpitaion
    • Decreased sexual ability
    • Bradycardia
    • Dizziness
    • Fatigue
    • Hypotension

    Bendroflumethiazide

    • Hypotension
    • Anorexia, epigastric distress
    • Phototoxicity
    • Hypercalcemia
    • Hyperuricemia
    • Hyperlipidemia
    • Hypercholesterolemia
    • Hypochloremia
    • Hypokalemia (common)
    • Hypomagnesemia
    • Hyponatremia
    • Glucose intolerance

    Anesthesia/surgery (myocardial depression); chronically administered beta-blocking therapy should not be routinely withdrawn prior to major surgery, however the impaired ability of the heart to respond to reflex adrenergic stimuli may augment the risks of general anesthesia and surgical procedures

    Bronchospastic disease

    Cerebrovascular insufficiency

    CHF, beta blockade carries the potential hazard of further depressing myocardial contractility and precipitating more severe failure

    DM, fluid or electrolyte imbalance, hyperuricemia or gout, hypotension, SLE

    Liver disease

    May aggravate digitalis toxicity

    Peripheral vascular disease

    Renal impairment

    Risk of male sexual dysfunction

    Sensitivity reactions may occur with or without history of allergy or asthma

    May interfere with phenolsulfonphthalein test; may produce false negatives in phentolamine and tyramine tests

    Avoid abrupt withdrawal

    Pregnancy Category : C

    Lactation: excreted in breast milk, use caution

    Adults

    80 mg/day PO nadolol and 5 mg/day PO bendroflumethiazide.

    Elderly

    80 mg/day PO nadolol and 5 mg/day PO bendroflumethiazide.

    Adolescents

    Safety and efficacy have not been established.

    Children

    Safety and efficacy have not been established.

    nadolol/bendroflumethiazide

    tablet

    • 40mg/5mg
    • 80mg/5mg